Document:

<PAGE>

                                                                   EXHIBIT 10.15

                                LEASE AGREEMENT
                                 ---------------

LANDLORD:               SALARI ENTERPRISE LTD.

ADDRESS OF PREMISE:     1080 Howe Street, Suite 501, Vancouver, BC, V6Z 1P5

TENANT:                 CHEMOKINE THERAPEUTICS CORP.

TENANT'S ADDRESS:       2386 East Mall (UBC), Unit 208, Vancouver, BC, V6T 1Z3

TERM:                   Five (5) years.

COMMENCEMENT DATE:      January 01, 2003

BASIC RENT:             $2,000 per month, plus GST ($2,000 + $140; total $2,140)

SCOPE OF ACTIVITY:      Biopharmaceutical business activity

PARKING PERMIT:         One (1) parking included in the price, (slot #11)

DEPOSIT:                One (1) month; $2,070

LANDLORD'S WORK:        Tenant is responsible for all the improvement costs.

RENEWAL TERM:           One (1) Option to Renew for a term of 1 year.

EARLY TERMINATION;      Tenant has the right to terminate the Lease at any time
prior to the end of the Term. However, Tenant is responsible for the full
payment of the remaining Lease from the date of early termination notice to the
end of the 5-year term.

The parties in consideration of the covenants and agreements in this Lease
contained, covenant and agree each with the other that the terms herein shall
form the Lease Agreement, and the parties shall be bound by the same. The Laws
of the Province of British Columbia govern this Agreement.

IN WITNESS WHEREOF the Landlords, the Tenant have executed this Lease as of the
01st day of January 2003.

Landlord:                                         Tenant:
SALARI ENTERPRISES LTD.                           CHEMOKINE THERAPEUTICS CORP.

/s/ Hassan Salari                                 /s/ Walter Korz

Authorized Signatory                              Authorized Signatory<PAGE>

                                                                   EXHIBIT 10.16

THE WARRANTS AND THE COMMON SHARES DELIVERABLE UPON EXERCISE THEREOF HAVE NOT
BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "U.S.
SECURITIES ACT") OR UNDER ANY STATE SECURITIES LAWS. THESE WARRANTS AND THE
UNDERLYING COMMON SHARES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO
U.S. PERSONS UNLESS THESE WARRANTS AND THE UNDERLYING COMMON SHARES ARE
REGISTERED UNDER THE U.S. SECURITIES ACT, OR AN EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF THE U.S. SECURITIES ACT IS AVAILABLE. HEDGING TRANSACTIONS
INVOLVING THESE WARRANTS AND THE UNDERLYING COMMON SHARES MAY NOT BE CONDUCTED
UNLESS IN COMPLIANCE WITH THE U.S. SECURITIES ACT. THE HOLDER HEREOF, AGREES FOR
THE BENEFIT OF THE CORPORATION THAT THESE WARRANTS AND THE UNDERLYING COMMON
SHARES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED ONLY (A) TO THE
CORPORATION, (B) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE U.S.
SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER OR ANOTHER APPLICABLE EXEMPTION,
OR (C) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT. DELIVERY OF THIS
CERTIFCATE MAY NOT CONSTITUTE "GOOD DELIVERY" IN SETTLEMENT OF TRANSACTIONS ON
STOOCK EXCHANGES IN CANADA.

THIS WARRANT MAY NOT BE EXERCISED ON BEHALF OF ANY U.S. PERSON UNLESS REGISTERED
UNDER THE U.S. SECURITIES ACT OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE.

UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST
NOT TRADE THE SECURITY BEFORE THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE
LATER OF (i) MAY 6, 2004, AND (II) THE DATE THE ISSUER BECAME A REPORTING ISSUER
IN ANY PROVINCE OR TERRITORY.

ANY SHARE CERTIFICATE ISSUED PURSUANT TO AN EXERCISE OF THESE WARRANTS BEFORE
THE LATER OF (i) MAY 6, 2004, AND (II) THE DATE THE ISSUER BECAME A REPORTING
ISSUER IN ANY PROVINCE OR TERRITORY MUST CONTAIN THE FOLLOWING LEGEND:

         "UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS
         SECURITY MUST NOT TRADE THE SECURITY BEFORE THE DATE THAT IS 4 MONTHS
         AND A DAY AFTER THE LATER OF (i) MAY 6, 2004, AND (II) THE DATE THE
         ISSUER BECAME A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY."

THE WARRANTS REPRESENTED HEREBY WILL BE VOID AND OF NO VALUE UNLESS EXERCISED
WITHIN THE TIME LIMIT HEREIN PROVIDED.

                     NON-TRANSFERABLE SHARE PURCHASE WARRANT

                          CHEMOKINE THERAPEUTICS CORP.
             (Incorporated under the laws of the State of Delaware)

No. 2004/01/ --                         Representing -- Share Purchase Warrants
                                        (the "Warrants") entitling the
                                        Warrantholder to purchase -- Common
                                        Shares

THIS IS TO CERTIFY that, for value received, -- (the "Warrantholder"), of --, --
--, has the right to purchase from CHEMOKINE THERAPEUTICS CORP. (the "Company"),
upon and subject to the terms and conditions hereinafter referred to -- fully
paid and

<PAGE>
                                     - 2 -

non-assessable common shares of the Company at the price (the "Shares") at the
price of $1.00 per Share if exercised at any time until 4:30 p.m. (Vancouver
time) on May 6, 2006 (the "Expiry Time").

THE FOLLOWING ARE THE TERMS AND CONDITIONS OF THE WARRANTS:

1.       The right to purchase Shares granted by this Warrant Certificate may
         only be exercised by the Warrantholder within the times set out above
         by:

         (a)   completing and executing the Exercise Form attached to this
               Warrant Certificate in the manner indicated;

         (b)   surrendering this Warrant Certificate to Chemokine Therapeutics
               Corp. c/o Thomas, Rondeau, Suite 1525 - 625 Howe Street,
               Vancouver, B.C., V6C 2T6; and

         (c)   paying the appropriate purchase price for the Shares subscribed
               for either by cash, certified cheque or bank draft payable at par
               in Vancouver, British Columbia.

2.       Upon surrender of this Warrant Certificate and receipt of payment, the
         Company will issue to the Warrantholder the appropriate number of
         Shares issuable in accordance with the terms and conditions of this
         Warrant Certificate not exceeding those which the Warrantholder is
         entitled to at the time of exercise. If the Warrantholder exercises a
         portion of the Warrants represented by this Warrant Certificate, he or
         she will be entitled to receive, without charge, a new Warrant
         Certificate representing the unexercised portion of the Warrants
         represented herein.

3.       After the full or partial exercise by the Warrantholder, the Company
         will cause to be mailed or delivered certificate(s) for the number of
         Shares issuable to the Warrantholder within three days at the address
         specified in the register for the Warrants maintained by the Company.

4.       The right to purchase Shares represented hereby has been issued by the
         Company in reliance upon the prospectus exemptions contained in
         applicable securities legislation. Consequently, any resale of the
         Shares by the Warrantholder is subject to any applicable resale
         restrictions contained in such legislation.

5.       The Warrantholder hereby agrees to comply with all applicable
         securities legislation in connection with the holding of the Warrants
         and the holding and exercise of the Shares issuable upon exercise of
         the Warrants.

6.       The Warrants evidenced by this Warrant Certificate are not transferable
         except where a person furnishes that he is, to the reasonable
         satisfaction of the Company:

         (a)   the executor, administrator, heir or legal representative of the
               heirs of the estate of a deceased Warrantholder;

         (b)   a guardian, committee, trustee, curator or tutor representing a
               Warrantholder who is an infant, an incompetent person or a
               missing person; or

         (c)   a liquidator or, or a trustee in bankruptcy for, a Warrantholder,

         and surrenders such evidence together with the Warrant Certificate in
         question to the Company (by delivery or mail as set forth herein), and
         such further reasonable requirements as the Company and all applicable
         securities regulatory authorities may prescribe at which time such
         person will become noted upon the register of Warrantholders. After
         receiving the surrendered Warrant Certificate and upon the person
         surrendering the Warrant Certificate meeting the

<PAGE>
                                     - 3 -

         requirements as hereinbefore set forth, the Company shall forthwith
         cause a new Warrant Certificate to be issued and sent to the new holder
         and the Company shall alter the register of Warrantholders accordingly.

7.       Subject to the provisions of this Warrant Certificate and applicable
         law, each Warrantholder is entitled to the rights and privileges
         attaching to the Warrants, and the issue of the Shares by the Company
         on exercise of Warrants by any Warrantholder in accordance with the
         terms and conditions herein contained discharges all responsibilities
         of the Company with respect to such Warrants and the Company is not
         bound to inquire into the title of any such registered holder.

8.       Nothing in this Warrant Certificate or in the holding of Warrants
         evidenced by this Warrant Certificate, or otherwise, shall be construed
         as conferring upon a Warrantholder any right or interest whatsoever as
         a shareholder, including but not limited to the right to vote at, to
         receive notice of, or to attend meetings of shareholders or any other
         proceedings of the Company or the right to receive any dividend and
         other distribution except as otherwise provided herein.

9.       The Company hereby covenants and agrees as follows:

         (a)   all Shares which may be issued upon exercise of this Warrant
               Certificate, in accordance with the respective terms thereof,
               will be validly issued, fully paid and non-assessable and free
               from any and all taxes, liens and charges with respect to the
               issue thereof (other than taxes in respect of any transfer
               occurring contemporaneously with such issue); and

         (b)   during the period within which the Warrants may be exercised, the
               Company will at all times have authorized and reserved a
               sufficient number of Shares to provide for the respective
               exercise of the Warrants.

10.      All Warrants in this series shall rank pari passu, notwithstanding the
         actual date of issue thereof.

11.      The Warrantholder may at any time up to the Expiry Time, upon written
         instruction delivered to the Company and payment of applicable charges,
         exchange this Warrant Certificate for other Warrant Certificates
         evidencing Warrants entitling the Warrantholder to acquire in the
         aggregate the same number of Shares as may be acquired under this
         Warrant Certificate.

12.      If any time after the date hereof and prior to the Expiry Time, and
         provided that any Warrants remain unexercised, there shall be:

         (a)   a reclassification of the Shares outstanding at the time or a
               change in the Shares into other shares or securities or a
               subdivision or consolidation of the Shares into a greater or
               lesser number of Shares, or any other capital reorganization; or

         (b)   a consolidation, amalgamation or merger of the Company with or
               into any other Company (other than a consolidation, amalgamation
               or merger which does not result in any reclassification of the
               outstanding common shares or a change of the common shares into
               other share or securities),

         (any of such events being call a "Capital Reorganization"), the
         Warrantholder which thereafter shall exercise or be deemed to have
         exercised its right to acquire the Shares pursuant to this Warrant
         Certificate shall be entitled to receive, at no additional cost, and
         shall accept in lieu of the number of the Shares to which such
         Warrantholder was theretofore entitled upon such exercise, the
         aggregate number of shares, warrants, other securities or other
         property which the
<PAGE>
                                     - 4 -

         Warrantholder should have been entitled to receive as a result of such
         Capital Reorganization if, on the effective date or record date thereof
         as the case may be, the Warrantholder had been the registered
         shareholder of the number of the Shares to which the Warrantholder was
         theretofore entitled to acquire upon exercise or deemed exercise of
         this Warrant Certificate. If determined appropriate by the Company
         acting reasonably, appropriate adjustments shall be made as a result of
         any such Capital Reorganization in the application of the provisions
         set forth herein with respect to the rights and interests thereafter of
         the Warrantholder to the end that the provisions set forth herein shall
         thereafter correspondingly be made applicable as nearly as may
         reasonably be in relation to any warrants, other securities or other
         property thereafter deliverable upon the exercise of any Warrants. Any
         such adjustment shall be made by and approved by the directors and
         shall for all purposes be conclusively deemed to be an appropriate
         adjustment.

13.      The adjustments provided for herein are cumulative and such adjustments
         shall be made successively whenever an event referred to herein shall
         occur, subject to the limitations provided for herein.

14.      No adjustments shall be made in the number or kind of Shares or other
         securities which may be acquired on the exercise of a Warrant unless it
         would result in a change of at least one-hundredth of a Share
         (provided, however, that any adjustments which may by reason of this
         paragraph not be required to be made, shall be carried forward and then
         taken into consideration in any subsequent adjustment).

15.      No adjustment shall be made in respect of any event described herein,
         if the Warrantholder is entitled to participate in such event on the
         same terms, without amendment, as if the Warrantholder had exercised
         his or her Warrants prior to or on the effective date or record date of
         such event.

16.      In the event of any question arising with respect to any adjustment
         provided for herein, such question shall be conclusively determined by
         a firm of chartered accountants appointed by the Company at its sole
         discretion (which may be the Company's auditors) and any such
         determination shall be binding upon the Company and the Warrantholder.

17.      As a condition precedent to the taking of any action which would
         require any adjustments in any of the subscription rights pursuant to
         any of the Warrants, the Company shall take any corporate action which
         may, in the opinion of counsel of the Company, be necessary in order
         that the Company have unissued and reserved in its authorized capital
         and may validly and legally issue as fully paid and non-assessable all
         the securities which the Warrantholder of such Warrants is entitled to
         receive on the exercise of all the subscription rights attaching
         thereto in accordance with the provisions thereof.

18.      In case the Company, after the date hereof, shall take any action
         affecting any securities of the Company, other than as previously set
         out herein, which in the opinion of the directors of the Company would
         materially affect the rights of the Warrantholder, the number of Shares
         which shall be issuable on the exercise or deemed exercise of the
         Warrants shall be adjusted in such manner, if any, and at such time, as
         the directors, in their sole discretion, may determine to be equitable
         in the circumstances provided that no such adjustment will be made
         unless all necessary regulatory approvals, if any, have been obtained.
         Failure of the taking of action by the directors so as to provide for
         such an adjustment prior to the effective date of any action by the
         Company affecting any securities of the Company shall be evidence that
         the directors have determined that it is equitable to make no
         adjustments in the circumstances.

<PAGE>
                                     - 5 -

19.      Notwithstanding any adjustments provided for herein or otherwise, the
         Company shall not be required upon the exercise of any Warrants, to
         issue fractional Shares in satisfaction of its obligations hereunder
         and except as provided for herein, any fractions shall be eliminated.
         To the extent that the Warrantholder would otherwise be entitled to
         acquire a fraction of a Share, such right may be exercised in respect
         of such fraction only in combination with other rights which in the
         aggregate entitle the Holder to acquire a whole number of Shares.

20.      In any situation where an event occurs which results in an increase in
         the number of Shares which may be issuable on the exercise or deemed
         exercise of the Warrants taking effect immediately after the record
         date for a specific event, if any Warrant is exercised after that
         record date and prior to completion of the event, the Company may
         postpone the issuance, to the Warrantholder, of the Shares to which the
         Warrantholder is entitled by reason of such adjustment, but such Shares
         shall be so issued and delivered to the Warrantholder upon completion
         of that event, with the number of such Shares calculated on the basis
         of the number of Shares provided for after the adjustment provided for
         herein on the date of exercise of the Warrants adjusted for completion
         of that event and the Company shall deliver to the person or persons in
         whose name or names the Shares are to be issued an appropriate
         instrument evidencing the right of such person or persons to receive
         such Shares and the right to receive any dividends or other
         distributions which, but for the provisions of this paragraph, such
         person or persons would have been entitled to receive in respect of
         such securities from and after the date that the Warrants were
         exercised in respect thereof.

21.      In case this Warrant Certificate shall become mutilated or be lost,
         destroyed or stolen, the Company, subject to applicable law, shall
         issue and deliver a new Warrant Certificate representing the Warrants
         of like date and tenor as the one mutilated, lost, destroyed or stolen
         upon surrender of and in place of and upon cancellation of the
         mutilated Warrant Certificate or in lieu of and in substitution for the
         lost, destroyed or stolen Warrant Certificate. The applicant for the
         issue of a new Warrant Certificate representing the Warrants pursuant
         to this section shall bear the cost of the issue thereof and in case of
         loss, destruction or theft shall, as a condition precedent to the issue
         thereof, furnish to the Company such evidence of ownership and of the
         loss, destruction or theft of the Warrant Certificate so lost,
         destroyed or stolen as shall be satisfactory to the Company and in its
         discretion and the applicant may also be required to furnish an
         indemnity in amount and form satisfactory to the Company in its
         discretion, and shall pay the reasonable charges of the Company in
         connection therewith.

22.      Any notice or delivery or surrender of documents shall be valid and
         effective if delivered personally or if sent by registered letter,
         postage prepaid, or if electronically transmitted by facsimile
         transmission tested for reception prior to use, addressed to:

         (a)   Chemokine Therapeutics Corp., c/o Thomas Rondeau, Suite 1525 -
               625 Howe Street, Vancouver, British Columbia, V6C 2T6,
               facsimile number (604) 688-6995; and

         (b)   the Warrantholder at the address on the first page hereof.

         and shall be deemed to have been effectively given, received and made
         on the date of personal delivery or on the fourth Business Day after
         the time of mailing or upon actual receipt, whichever is sooner, or
         upon the day, other than Saturday, Sunday or a statutory holiday, after
         the time of facsimile transmission. In the case of disruption in postal
         services any notice, if mailed, shall not be deemed to have been
         effectively given until it is personally delivered. The Company or the
         Warrantholder may from time to time notify the other in writing of a
         change of address.

<PAGE>
                                     - 6 -

23.      The Warrants represented by this certificate may be exercised in whole
         or in part from time to time, and this certificate may be exchanged,
         upon its surrender to the Company, for new Warrant Certificates of like
         tenor in denominations which represent in the aggregate the right to
         subscribe for and receive the number of Shares which may be subscribed
         for hereunder. If the Warrants represented by this certificate are
         exercised in part, the Company shall deliver with the Shares acquired
         on such exercise, a new Warrant Certificate representing the balance of
         the Warrants remaining unexercised.

24.      Unless the Warrants and Shares are registered under the U.S. Securities
         Act, each Warrantholder exercising a Warrant shall be required to give
         (A) written certification that Warrantholder is not a U.S. person and
         the Warrant is not being exercised on behalf of a U.S. person; or (B) a
         written opinion of counsel to the effect that the Warrant and the
         securities delivered upon exercise thereof have been registered under
         the U.S. Securities Act or are exempt from registration thereunder.
         Further the Company may implement procedures to ensure that the Warrant
         may not be exercised within the United States, and that the Shares may
         not be delivered within the United States upon exercise, other than in
         offerings deemed to meet the definition of "offshore transaction"
         pursuant to Regulation S Section 230.902(h), unless registered under
         the U.S. Securities Act or an exemption from such registration is
         available.

25.      The Warrants and the Shares are deemed to be "restricted securities" as
         defined in SEC Rule Section 230.144. Resales of any of such restricted
         Warrants and Shares by a non-U.S. Person must be made in accordance
         with SEC Regulation S, the registration requirements of the U.S.
         Securities Act or an exemption therefrom. The Warrants and the Shares
         will continue to be deemed to be restricted securities, notwithstanding
         that they were acquired in a resale transaction made pursuant to SEC
         Regulation S Section 230.901 or Section 230.904.

26.      Unless the Warrants and Shares are registered under the U.S. Securities
         Act, the offer or sale of the Warrant or the Shares by the
         Warrantholder, if made prior to the expiration of a one-year
         distribution compliance period (as defined in SEC Regulation S), is not
         made to a U.S. person or for the account or benefit of a U.S. person;
         and the offer or sale of the Warrant or the Shares by the
         Warrantholder, if made prior to the expiration of a one-year
         distribution compliance period (as defined in SEC Regulation S), is
         made pursuant to the following conditions: (1) The purchaser of the
         Warrant or the Shares certifies that it is not a U.S. person and is not
         acquiring the Warrant or the Shares for the account or benefit of any
         U.S. person or is a U.S. person who purchased the Warrant or the Shares
         in a transaction that did not require registration under the Act. (2)
         The purchaser of the Warrant or the Shares agrees to resell such
         securities only in accordance with the provisions of SEC Regulation S,
         pursuant to registration under the U.S. Securities Act, or pursuant to
         an available exemption from registration; and agrees not to engage in
         hedging transactions with regard to the Warrant or the Shares unless in
         compliance with the U.S. Securities Act

27.      Time shall be of the essence hereof.

28.      After the exercise of any of the Warrants represented by this Warrant
         Certificate, the Warrantholder shall no longer have any rights under
         this Warrant Certificate with respect to such Warrants, other than the
         right to receive certificates representing the Shares issuable on the
         exercise of those Warrants, and those Warrants shall be void and of no
         further value or effect.

29.      This Warrant Certificate shall be construed in accordance with the laws
         of the Province of British Columbia and the laws of Canada applicable
         herein and shall be treated in all respects as a British Columbia
         contract.

<PAGE>
                                     - 7 -

IN WITNESS WHEREOF the Company has caused this Warrant Certificate to be signed
by its duly authorized officer as of the 6th day of May, 2004.

CHEMOKINE THERAPEUTICS CORP.

Per:
     ---------------------------------------
          Authorized Signing Officer

Share Purchase Warrant No. 2004/01/  --

<PAGE>
                                  EXERCISE FORM

TO:   CHEMOKINE THERAPEUTICS CORP.
      c/o Thomas, Rondeau
      1525-625 Howe Street
      Vancouver, B.C.
      V6C 2T6

--------------------------------------------------------------------------------

THE UNDERSIGNED Warrantholder hereby exercises the right to acquire ___________
common shares of CHEMOKINE THERAPEUTICS CORP., on the terms specified in the
Warrant Certificate.

The undersigned hereby directs that the said Shares be issued as follows:

=========================|==================================|===================
    NAME(S) IN FULL      |         ADDRESS(ES)              |  NUMBER OF SHARES
=========================|==================================|===================
                         |                                  |
                         |                                  |
-------------------------|----------------------------------|-------------------
                         |                                  |
                         |                                  |
=========================|==================================|===================

[Please print. If securities are issued to a person other than Warrantholder,
the Warrantholder must pay to the Company all eligible taxes and other duties
and the signature of the Warrantholder must be guaranteed.]

DATED this ____ day of _____________________, _______________ .

______________________________________   _______________________________________
Signature Witnessed or Guaranteed        (Signature of Warrantholder to be the
(See instructions to Warrantholders      same as appears on the face of this
below)                                   Warrant Certificate)

Name of Warrantholder:                __________________________________________

Address (PLEASE PRINT):               __________________________________________

                                      __________________________________________

Unless the Warrants and Shares are registered under the U.S. Securities Act each
Warrantholder exercising a Warrant shall provide the following certification or
include an opinion of counsel to the effect that the Warrant and the securities
delivered upon exercise thereof have been registered under the U.S. Securities
Act or are exempt from registration thereunder.

The undersigned Warrantholder hereby certifies that Warrantholder is not a U.S.
Person (as defined in Regulation S under the U.S. Securities Act of 1933) and
the Warrant is not being exercised on behalf of a U.S. Person

                                      __________________________________________
                                      (Signature of Warrantholder)

<PAGE>

                         INSTRUCTIONS TO WARRANTHOLDERS

TO EXERCISE:

         If the Warrantholder exercises Warrants prior to the Expiry Time
         pursuant to this Warrant Certificate, it must deliver the Warrant
         Certificate and complete, sign and deliver the Exercise Form to the
         Company indicating the number of Shares to be acquired. In such case,
         the signature of such registered holder on the Exercise Form must be
         witnessed or guaranteed, as the case may be.

         If this exercise form indicates that the common shares and warrants are
         to be issued to a person or persons other than the registered holder of
         this Warrant Certificate, the signature of such holder on the exercise
         form must be guaranteed by an authorized officer of a chartered bank,
         trust company or Medallion Guaranteed by an investment dealer who is a
         member of a recognized stock exchange.

GENERAL:

If the Exercise Form is signed by a trustee, executor, administrator, curator,
guardian, attorney, officer of a corporation or any person acting in a fiduciary
or representative capacity, the Warrant Certificate must also be accompanied by
evidence of authority to sign satisfactory to the Company.

The name and address of the Company is:

                          CHEMOKINE THERAPEUTICS CORP.
                               c/o Thomas, Rondeau
                          Suite 1525 - 625 Howe Street
                                 Vancouver, B.C.
                                     V6C 2T6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]